Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

References

• SegalJBPoweNRPrevalence of immune thrombocytopenia: analyses of administrative dataJ Thromb Haemost20064112377238316869934
   PubMed Web of Science ®Google Scholar
• TerrellDRBeebeLAVeselySKNeasBRSegalJBGeorgeJNThe incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAm J Hematol201085317418020131303
   PubMed Web of Science ®Google Scholar
• AltomareICetinKWettenSWasserJSRate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the USClin Epidemiol2016823123927382333
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood InstituteImmune Thrombocytopenia2012 Available from: https://www.nhlbi.nih.gov/health-topics/immune-thrombocytopeniaAccessed September 26, 2018
   Google Scholar
• ChengGSalehMNMarcherCEltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyLancet2011377976339340220739054
   PubMed Web of Science ®Google Scholar
• NeunertCECurrent management of immune thrombocytopeniaHematology Am Soc Hematol Educ Program20132013127628224319191
   PubMed Web of Science ®Google Scholar
• ChicheLPerrinASternLKutikovaLCohen-NizardSLefrèreFCost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in FranceTransfus Clin Biol2014212859324797790
   PubMed Web of Science ®Google Scholar
• dos SantosRFVargas-ValenciaJJGiannopoulouACampioniMCost-Effectiveness Analysis of Romiplostim for The Treatment of Adult Chronic Immune Thrombocytopenic Purpura (Itp) In BrazilValue Health2015187A668
   Web of Science ®Google Scholar
• LópezMFMingotMEValcárcelDVicente GarcíaVPerrinACampos TapiasICost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in SpainMed Clin20151449389396
   Web of Science ®Google Scholar
• PepeCTeichVCoutinhoMBAlmeidaSRomiplostim Cost Per Response In Itp Treatment In the Brazilian Health Care SystemValue Health2014177A529A529
   Web of Science ®Google Scholar
• AllenRBrainskyAGrotzingerKRocciaTA comment on Boyers et al.: “eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal”Pharmacoeconomics2013311878923329595
   PubMed Web of Science ®Google Scholar
• LiXSharmaAZhangXCost per Treatment Success of Thrombopoietin Receptor Agonists Vs “Watch and Rescue” Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer PerspectiveBlood20151264461
   Web of Science ®Google Scholar
• BellWRLong-term outcome of splenectomy for idiopathic thrombocytopenic purpuraSemin Hematol2000371 Suppl 1222510676920
   PubMed Web of Science ®Google Scholar
• SchwartzJLeberMDGillisSGiuntaAEldorABusselJBLong term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)Am J Hematol2003722949812555211
   PubMed Web of Science ®Google Scholar
• ArnoldDMHeddleNMCarruthersJA pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopeniaBlood201211961356136222223819
   PubMed Web of Science ®Google Scholar
• GhanimaWKhelifAWaageRITP study groupRituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trialLancet201538599781653166125662413
   PubMed Web of Science ®Google Scholar
• MoulisGSaillerLSommetALapeyre-MestreMDerumeauxHAdoueDRituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidityAm J Hematol2014891414624038066
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBLyonsRMEfficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialLancet2008371961039540318242413
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBLyonsRMEfficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialLancet2008371961039540318242413
   PubMed Web of Science ®Google Scholar
• BoyersDJiaXCrowtherMJenkinsonDFraserCMowattGEltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)Health Technol Assess201115Suppl 1233221609650
   PubMedGoogle Scholar
• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• United States Census BureauAnnual Population Growth Rate Available from: https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2015_PEPANNRES&src=ptAccessed September 26, 2018
   Google Scholar
• BoyleSWhiteRHBrunsonAWunTSplenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopeniaBlood2013121234782479023637127
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) National Cancer Institute, US National Institutes of Health2006 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdfAccessed September 26, 2018
   Google Scholar
• ChengGSalehMNMarcherCEltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyLancet2011377976339340220739054
   PubMed Web of Science ®Google Scholar
• AnalySource: Premier Drug Pricing ServicesSyracuse, NY2017 Available from: https://www.analysource.com/Accessed September 26, 2018
   Google Scholar
• SalehMNFisherMGrotzingerKMAnalysis of the impact and burden of illness of adult chronic ITP in the USCurr Med Res Opin200925122961296919835465
   PubMed Web of Science ®Google Scholar
• LeeDThorntonPHirstAKutikovaLDeusonRBreretonNCost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in IrelandAppl Health Econ Health Policy201311545746923857462
   PubMedGoogle Scholar
• TonerRWPizziLLeasBBallasSKQuigleyAGoldfarbNICosts to Hospitals of Acquiring and Processing Blood in the USAppl Health Econ Health Policy201191293721174480
   PubMedGoogle Scholar
• Centers for Medicare & Medicaid ServicesMedicare – ASP Drug Pricing Files [Internet]Medicare2016 [cited October 2016]. Available from: https://www.cms.gov/apps/ama/license.asp?file=/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/Downloads/2016-October-ASP-Pricing-File.zipAccessed September 26, 2018
   Google Scholar
• LinJZhangXLiXCost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United StatesClin Ther20173933274609
   Web of Science ®Google Scholar
• CMS Medicare Fee Schedule [Internet]Medicare2017 Available from: https://www.findacode.com/Accessed September 26, 2018
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). US Department of Health & Human Services2013 Available from: https://hcupnet.ahrq.gov/#setupAccessed September 26, 2018
   Google Scholar
• JansenJPNaciHIs network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiersBMC Med201311115923826681
   PubMed Web of Science ®Google Scholar
• US Department of LaborInflation Rate 2015–2016US Bureau of Labor Statistics (CPI)2015 Available from: https://www.bls.gov/news.release/archives/cpi_07152016.pdfAccessed September 26, 2018
   Google Scholar